Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation

Blood

Volumn 88, Issue 5, 1996, Pages 1788-1795

  Zhao, Qiuyan ^b   Song, Xengxuan ^b   Waldschmidt, Thomas ^b   Fisher, Eric ^b   Krieg, Arthur M ^a  

^a UNIVERSITY OF IOWA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD4 ANTIGEN; CD8 ANTIGEN; GROWTH FACTOR; INTERLEUKIN 3; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RETINOIC ACID; STEM CELL FACTOR;

ARTICLE; CELL PROLIFERATION; CELL STRAIN HL 60; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG EFFICACY; DRUG UPTAKE; GENE EXPRESSION REGULATION; HELPER CELL; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; INTERNALIZATION; LEUKEMIA; PRIORITY JOURNAL;

EID: 0029819705     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.5.1788.bloodjournal8851788     Document Type: Article

References (27)

1. Stein CA, Cheng YC: Antisense oligonucleotides as therapeutic agents-is the bullet really magical? [Review]. Science 261:1004, 1993
2. Lisziewicz J, Sun D, Weichold FF, Thierry AR, Lusso P, Tang J, Gallo RC, Agrawal S: Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sci USA 91:7942,1994
3. Agrawal S: Antisense oligonucleotide approach for therapy of AIDS, in Mohan P, Baba B (eds): Anti-AIDS Drug Development: Challenges, Strategies and Prospects. Amsterdam, The Netherlands, Harwood Academic, 1995, p 143
4. Agrawal S, Iyer RP: Modified oligonucleotides as therapeutic and diagnostic agents. Curr Opin Biotechnol 6:12, 1995
5. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J Pharmacol Exp Ther 269:89,1994
6. Bayever E, Iversen P: Oligonucleotides in the treatment of leukemia. [Review]. Hematol Oncol 12:9,1994
7. Bennett RB: As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells. [Review]. Antisense Res Dev 3:235, 1993
8. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM: Proc Natl Acad Sci USA 86:3474, 1989
9. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov VV: Proc Natl Acad Sci USA 86: 6454, 1989
10. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM: Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95:1814, 1995
11. Krieg AM, Gmelig-Meyling F, Gourley MF, Kisch WJ, Chrisey LA, Steinberg AD: Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. Antisense Res Dev 2:161, 1991
12. Iversen PL, Crouse D, Zon G, Perry G: Binding of antisense phosphorothioate oligonucleotides to murine lymphocytes is lineage specific and inducible. Antisense Res Dev 2:223, 1992
13. Zhao Q, Matson S, Herrera CJ, Fisher E, Yu H, Krieg AM: Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev 3:53, 1993
14. Hiddemann GA, Griesinger F: Preclinical aspects and therapeutic perspectives of acute and chronic leukemias [Review]. Curr Opin Oncol 5:13, 1993
15. Hartwell LH, Kastan MB: Cell cycle control and cancer [Review], Science 266:1821, 1994
16. Gewirtz AM: Oligodeoxynucleotide-based therapeutics for human leukemias. Stem Cells 11:96, 1993
17. Calabretta B, Skorski T, Szczylik C, Caracciolo D, Valtieri M, Venturelli D: Protooncogenes in the regulation of normal hematopoiesis, an antisense approach. Ann NY Acad Sci 660:178, 1992
18. Kregenow D, Ratajeczak MZ, Gewirtz AM: Disrupting the flow of genetic information with antisense oligodeoxynucleotides: Research and Therapeutic Applications, in Akhtar S (ed): Delivery Strategies for Antisense Oligonucleotide Therapeutics. Boca Raton, FL, CRC, 1995, p 1
19. Beaucage SL: Oligodeoxyribonucleotide synthesis: Phosphoramidite approach, in Agrawal S (ed): Methods in Molecular Biology: Protocols for Oligonucleotides and Analogs. (vol 26) Totowa, New Jersey, Humana, 1993, p 33
20. Schubert F, Ahlert K, Cech D, Rosenthal A: One-step labeling of oligonucleotides with fluorescein during automated synthesis. Nucleic Acids Res 18:3427,1990
21. Temsamani J, Kubert M, Agrawal S: A rapid method for quantitation of oligodeoxynucleotide phosphorothioates in biological fluids and tissues. Anal Biochem 215:54, 1993
22. Krieg AM: Uptake and localization of phosphodiester and chimeric oligodeoxynucleotides in normal and leukemic cells, in Akhtar S (ed): Delivery Strategies for Antisense Oligonucleolide Therapeutics. Boca Raton, FL, CRC, 1995, p 177
23. Holdener EE, Bollag W: Retinoid [Review]. Curr Opin Oncol 5:13, 1993
24. Tonkinson JL, Stein CA: Patterns of intracellular compartmentalization, trafficking and acidification of 5′-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL-60 cells. Nucleic Acids Res 22:4268, 1994
25. Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM: Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: An in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA 88:2351, 1991
26. Zhao Q, Waldschmidt T, Fisher E, Herrera CJ, Krieg AM: Stage specific Oligonucleotide uptake in murine bone marrow B cell precursors. Blood 84: 3660, 1995
27. Hoeler D: Treatment of acute lymphoblastic leukemia. Semin Hematol 31:1, 1994